Q1 Earnings Forecast for PBH Issued By William Blair

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Prestige Consumer Healthcare in a research note issued to investors on Thursday, May 8th. William Blair analyst J. Andersen forecasts that the company will earn $0.98 per share for the quarter. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. William Blair also issued estimates for Prestige Consumer Healthcare’s Q2 2026 earnings at $1.22 EPS, Q3 2026 earnings at $1.25 EPS, Q4 2026 earnings at $1.29 EPS and FY2027 earnings at $5.00 EPS.

A number of other equities analysts have also recently commented on PBH. StockNews.com cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Friday. Canaccord Genuity Group raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Oppenheimer lifted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. DA Davidson boosted their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Hold” and a consensus target price of $93.33.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $87.65 on Monday. The firm’s fifty day moving average price is $83.18 and its 200-day moving average price is $81.45. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The stock has a market cap of $4.34 billion, a P/E ratio of 20.53, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare has a fifty-two week low of $62.35 and a fifty-two week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.02. The business had revenue of $296.52 million for the quarter, compared to analysts’ expectations of $289.36 million. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.02 EPS.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently added to or reduced their stakes in PBH. Allspring Global Investments Holdings LLC increased its stake in shares of Prestige Consumer Healthcare by 3.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock worth $126,274,000 after purchasing an additional 49,331 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Prestige Consumer Healthcare by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company’s stock worth $105,342,000 after purchasing an additional 21,951 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter worth $84,932,000. Invesco Ltd. increased its stake in shares of Prestige Consumer Healthcare by 2.4% in the fourth quarter. Invesco Ltd. now owns 1,060,263 shares of the company’s stock worth $82,796,000 after purchasing an additional 24,392 shares in the last quarter. Finally, Congress Asset Management Co. increased its stake in shares of Prestige Consumer Healthcare by 9.1% in the first quarter. Congress Asset Management Co. now owns 991,580 shares of the company’s stock worth $85,246,000 after purchasing an additional 82,838 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Insider Activity at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. The trade was a 8.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by company insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.